More than 2 million people have registered to become stem cell donors the UK, new figures released today reveal. The UK stem cell register had an immensely successful year in 2019/20, with 326,756 new donors added over 100,000 more than the previous year.

The UK stem cell register is known as the Anthony Nolan and NHS Stem Cell Registry and is made up of donors recruited by NHS Blood and Transplant, the Welsh Blood Service, DKMS and Anthony Nolan. The UK donor registers are urging young men, and people from black, Asian and minority ethnic backgrounds to register and ensure that all patients in need of a stem cell transplant can find a, potentially, lifesaving match.

If a patient has a condition that affects their bone marrow or blood, then a stem cell transplant may be their best chance of survival. Doctors will give new, healthy stem cells to the patient via their bloodstream, where they begin to grow and create healthy red blood cells, white blood cells and platelets.

In 2019/20 62 per cent of people who donated stem cells or bone marrow to patients in the UK were men under 30. They are the demographic most likely to be chosen to donate, but make up just 19 per cent of the UK stem cell register.

The percentage of all donors from minority ethnic backgrounds has remained steady at 13 per cent in 2019/20, highlighting the importance of raising awareness of their lifesaving potential amongst this group. Patients from Black, Asian or other minority backgrounds have a 20 per cent chance of finding the best possible stem cell match from an unrelated donor, compared to 69 per cent for northern European backgrounds.

Henny Braund, Chief Executive of Anthony Nolan, said:

Nobody could have foreseen the challenges this year would bring to building a healthy, diverse stem cell register. But weve adapted and weve innovated as patients cant wait and were thrilled that in 2020, weve collectively recruited two million donors onto the stem cell register. Each donor represents hope, a potential cure for blood cancer.

I thank colleagues and partners for their commitment helping us reach this point. I am also immensely grateful for the two million selfless individuals who signed up to the registry, making themselves available whenever they are needed.

The two million milestone means increased chances for many of finding an unrelated donor match. But were still far from our goal of finding a match for everyone who needs one.

I would urge anyone thinking of joining the stem cell register, especially young men, who are the most likely to be chosen, to do so today. You could be someones lifesaver, without you there is no cure.

Christopher Harvey, Head of the Welsh Bone Marrow Registry, said:

Its incredibly heart-warming to know there are two million people in the UK who are willing to donate stem cells should they be the match for someone in need of their potentially lifesaving donation.

We see in our roles the difference stem cells make, for lots of patients receiving stem cells is the final treatment option.

Despite this great news we still have more to do. Unfortunately, there are still patients who are unable to find a match. Thats why were committed to ensuring every patient has the best possible chance of finding that one lifesaving donor in their time of need.

Guy Parkes, Head of Stem Cell Donation & Transplantation at NHS Blood and Transplant, said:

We want all patients in need of a transplant to be able to find a lifesaving match. Each time a person joins this register it brings fresh hope to patients of a match.

This register is used by hospitals across the UK to find suitable matches for patients and it has helped to save and improve the lives of thousands of people since its creation 33 years ago its amazing that we now have over 2 million people on the register, putting the chances of matching donors to patients at a record high.

Donating stem cells is an altruistic, lifesaving act and its an amazing thing to do. We will continue to expand the UK register to help patients in need. We particularly need more young men to join.

Jonathan Pearce, CEO of DKMS UK said:

Were delighted to have reached such an amazing milestone and are grateful to those two million people who are actively registered and waiting to help give someone living with blood cancer or a blood disorder a second chance of life.

At any one time there are around 2,000 people in the UK in need of a blood stem cell transplant, so whilst we recognise this achievement it goes without saying that we need to continue to encourage everyone that can register to do so. This will help to grow the numbers and diversify the registry further in order to improve the odds for those who currently have less chance of finding a matching donor.

Visit link:
The Anthony Nolan and NHS Stem Cell Registry - The Hippocratic Post

Bone Marrow Stem Cells Comments Off on The Anthony Nolan and NHS Stem Cell Registry – The Hippocratic Post | October 19th, 2020

"Young people today are often drivers of social change movements and we look forward to engaging them."

South African youth aged 16 and 17 will be able to make history, alongside their peers in the UK, as the worlds youngest bone marrow donors.

The South African Bone Marrow Registry (SABMR) received the nod from its Clinical Governance Committee and board members, as well as the National Health Department to allow 16 and 17-year-old teens to become bone marrow, stem-cell donors.

Recent changes in legislation and advances in stem cell donation have allowed registries to reduce the age limit of donors. South Africa now joins the UK in this move. The latter became one of the first countries to do so.

Dr Charlotte Ingram, Medical Director of the SA Bone Marrow Registry (SABMR) the largest registry in the country says it's a landmark moment as the change in joining policy will contribute to saving more lives.

"In general, young people make better donors. Research shows that younger donors are associated with better survival rates for patients following a stem cell transplant."

"It's a step towards further enhancing the registry towards a younger and more ethnically diverse pool for blood cancer patients and others in need of a bone marrow transplant."

Previously, teenagers had to wait until they were 18 to join the SA Bone Marrow Registry. Now they can join by following the same procedure as others would.

While it is not required, it is important for the SABMR to involve parents and address any questions or concerns they may have re the procedure and what it entails.

Once youth have applied online, they will be contacted to discuss the easiest way of dispatching and collecting swab kits. The only initial sample that is required is a cheek swab.

Currently, 18-25-year olds only account for 6.8% of the SABMR registry but with increased awareness of bone marrow donation among young people, the figure should increase substantially.

Read:Knowledge is key: What you need to know about the most common childhood cancer in SA

"Studies tell us that generation WE (aged 14-20) and generation Z (21-25) are a lot more self-aware, socially-responsible and globally-minded than previous generations. They are more concerned about tackling social issues and want to roll up their sleeves and make a difference. Young people today are often drivers of social change movements and we look forward to engaging them."

She says there is no greater way to help another than to potentially save a life.

"So many lives are lost if there is a delay in finding a donor match. While we have 74 000 donors on our registry, we often discover that many older donors can no longer donate stem cells as they have developed hypertension, heart disease or diabetes."

"When this happens, we have to start the search process all over again, which prolongs the agonising wait for a patient, who doesn't have time to waste."

"By opening up the donor pool to a younger audience, means doctors and donors can choose the healthiest matches that substantially increases a patients chance of survival."

For now, social media will serve as the primary channel to create awareness among youth, but physical donor drives at schools and other initiatives, which encourage collaboration between learners, peers and patients are in the pipeline for 2021.

If you are between the ages of 16 and 45 and want to become a donor, contact the SABMR on 021 447 8638 or email: donors@sabmr.co.za.

Financial donations can also be made via http://www.sabmr.co.za/donate.

Submitted to Parent24 by theSA Bone Marrow Registry

Chatback:

Share your stories and questions with us via email at chatback@parent24.com. Anonymous contributions are welcome.

Don't miss a story!

For a weekly wrap of our latest parenting news and advice sign up to our free Friday Parent24 newsletter.

Follow us, and chat, on Facebook and Twitter.

Excerpt from:
SA becomes 2nd country to allow 16 and 17-year-olds to donate bone marrow - News24

Bone Marrow Stem Cells Comments Off on SA becomes 2nd country to allow 16 and 17-year-olds to donate bone marrow – News24 | October 19th, 2020

DENVER A baby broken.

Most doctors gave little unborn Payton Calvillo any hope she would survive.

But through strong faith and the help of a team of medical experts, she is thriving today.

"She's a complete miracle baby," said Payton's mother, Ahna Calvillo.

When Ahna was just five months pregnant, she was told her unborn baby would probably not survive birth.

"It was pretty much a death sentence from the beginning."

Payton's bones were breaking and bending inside the womb.

"She likely had a problem where she couldn't make alkaline phosphatase properly," explained Dr. Sunil Nayak, a pediatric endocrinologist at Rocky Mountain Hospital for Children.

Alkaline phosphatase is needed for bones to grow and strengthen.

There was little anyone could do.

19 different specialists were on hand for the C-section delivery

"They even asked us the question that morning, how far do you want us to go?" Ahna remembered.

"'Do you want a ventilator on her?', you know, 'How far do you want us to prolong her life?'"

"Our ultimate hope and goal was that she would come out and breathe on her own."

"She just came out screaming," said Ahna.

"She came out crying. She breathed on her own right away. She was perfect."

Payton was diagnosed with hypophosphatasia, a disorder that weakens bones.

She was immediately placed on a new FDA-approved medicine.

"Here we are just one year later at one year of age and you see a dramatic difference in the shape," said Dr. Jared Riley, a pediatric orthopedic surgeon at Rocky Mountain Hospital.

Before the medicine, 75% of all patients died by the age of five.

Now there is a 97% chance Payton will live a normal life.

"My baby was broken and that's what I needed God to do was a miracle," said Ahna.

One was also treated with bone fragments and cultured osteoblasts, which are bone-forming cells.

"Cultured" refers to cells that are grown under specific conditions outside of the natural environment (the body) and within a laboratory.

Both patients showed significant, but incomplete improvement, although no more formal studies have been conducted.

Then, the drug teriparatide (parathyroid hormone 1-34) has been given "off-label" to several adults with HPP with metatarsal stress fractures or femoral pseudo fractures, resulting in healing.

The drug is not permitted for use in children.

More research is necessary to determine the long-term safety and effectiveness of teriparatide in the treatment of HPP.

Every year eight million babies are born with genetic disorders passed down from generation to generation.

Payton will stay on the new medication for the next few years and then doctors will re-evaluate whether she needs to continue.

Payton's family didn't even know they carried the problematic HPP gene until an ultrasound revealed it in their unborn baby.

After being genetically tested, Payton's mother and grandfather are positive.

Neither one has ever suffered from weak or broken bones.

If this story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Jim Mertens at jim.mertens@wqad.com or Marjorie Bekaert Thomas atmthomas@ivanhoe.com.

Read the original:
YOUR HEALTH: Saving an unborn baby breaking apart in the womb - WQAD.com

Bone Marrow Stem Cells Comments Off on YOUR HEALTH: Saving an unborn baby breaking apart in the womb – WQAD.com | October 19th, 2020

Global Stem Cell Therapy Market was valued at USD 117.66 million in 2019 and is projected to reach USD 255.37 million by 2027, growing at a CAGR of 10.97% from 2020 to 2027.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2020 to 2027.

The Stem Cell Therapy market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Stem Cell Therapy market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get a Sample Copy of the Stem Cell Therapy Market Report with Latest Industry Trends @ https://www.verifiedmarketresearch.com/download-sample/?rid=24113

Competitive Analysis:

The competitive analysis covers key players and the innovations and business strategies undertaken by them. The report captures the best long term growth opportunities for the sector and includes the latest process and product developments. The report includes basic information of the companies along with their market position, historical background, and market capitalization and revenue. The report covers revenue figures, market growth rate, and gross profit margin of each player based on regional classification and overall market position. The report provides a separate analysis of the recent business strategies such as mergers, acquisitions, product launches, joint ventures, partnerships, and collaborations.

Key features of the Report:

Leading players of Stem Cell Therapy including:

You can Buy This Report from Here @ https://www.verifiedmarketresearch.com/select-licence/?rid=24113

Market Breakdown:

The market breakdown provides market segmentation data based on the availability of the data and information. The market is segmented on the basis of types and applications.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

Request a discount on the report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113

To understand the global Stem Cell Therapy market dynamics, the market is analyzed across major global regions and countries. Market Research Intellect provides customized specific regional and country-wise analysis of the key geographical regions as follows:

North America: USA, Canada, Mexico

Latin America: Argentina, Chile, Brazil, Peru, and Rest of Latin America

Europe:K., Germany, Spain, Italy, and Rest of EU

Asia-Pacific: India, China, Japan, South Korea, Australia, and Rest of APAC

Middle East & Africa: Saudi Arabia, South Africa, U.A.E., and Rest of MEA

The report considers:

Historical Years: 2017-2018

Base Year: 2019

Estimated Year: 2020

Forecast Years: 2020-2027

Benefits of Stem Cell Therapy Market Report:

Report Overview with TOC:

Browse the complete report Along with TOC @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/

Thank you for reading our report. Customization of the report is also available on the basis of region and countries. Kindly get in touch with us for more information regarding the report and its customization. Our team will ensure the report is best suited according to your needs.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: sales@verifiedmarketresearch.com

See the article here:
Stem Cell Therapy Market To Observe Exponential Growth By 2020-2027 | Verified Market Research - Stock Market Vista

Bone Marrow Stem Cells Comments Off on Stem Cell Therapy Market To Observe Exponential Growth By 2020-2027 | Verified Market Research – Stock Market Vista | October 19th, 2020

NEW YORK, Oct. 15, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the third quarter ended September 30, 2020, and provided a corporate update.

"The most important near-term event for BrainStorm will be the upcoming top-line data readout for the NurOwn Phase 3 trial in ALS, expected by the end of November. A successful outcome will set us on the path to filing a Biologic License Application (BLA) for what we believe will be a valuable new treatment for ALS," said Chaim Lebovits, Chief Executive Officer of BrainStorm Cell Therapeutics. "In parallel to our preparations for upcoming data read out, we are very busy planning and executing on other pre-BLA activities. On the management front, we appointed William K. White and Dr. Anthony Waclawski, adding valuable commercial and regulatory expertise to our leadership team. This expertise will be crucial as we work towards obtaining regulatory approval for NurOwn and ensuring that, if approved, it will be readily accessible to ALS patients in need of new treatment options for this devastating disease."

NurOwn has an innovative mechanism of action that is broadly applicable across neurodegenerative diseases and BrainStorm continues to invest in clinical trials evaluating the product in conditions beyond ALS to maximize value creation for its various stakeholders. The company remains on track to complete dosing in its Phase 2 clinical trial in progressive multiple sclerosis (PMS) by the end of 2020. In addition, the Company recently unveiled a clinical development program in Alzheimer's' disease (AD) and is planning a Phase 2 proof-of-concept clinical trial at several leading AD centers in the Netherlands and France.

Third Quarter 2020 and Recent Corporate Highlights:

Presented at the following Investor Conferences:

Cash and Liquidity as of October 14, 2020

Total available funding as of October 14, 2020, which includes cash, cash equivalents and short-term bank deposits of approximately $33.1 million as well as remaining non-dilutive funding from CIRM, IIA and other grants, amounts to approximately $36 million.

Financial Results for the Three Months Ended September 30, 2020

Conference Call & WebcastThursday, October 15, 2020 at 8 a.m. Eastern TimeFrom the US:877-407-9205International: 201-689-8054Webcast:https://www.webcaster4.com/Webcast/Page/2354/37811

Replays, available through October 29, 2020From the US:877-481-4010International: 919-882-2331Replay Passcode: 37811

About NurOwn

NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received acceptance from theU.S. Food and Drug Administration(FDA) to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS) and completed enrollment inAugust 2020.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(FDA) and theEuropean Medicines Agency(EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at sixU.S.sites supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a filing forU.S.FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently receivedU.S.FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed enrollment inAugust 2020. For more information, visit the company's website atwww.brainstorm-cell.com.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

ContactsInvestor Relations:Corey Davis, Ph.D.LifeSci Advisors, LLCPhone: +1 646-465-1138[emailprotected]

Media:Paul TyahlaSmithSolvePhone: + 1.973.713.3768[emailprotected]

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIESINTERIM CONDENSED CONSOLIDATED BALANCE SHEETSU.S. dollars in thousands(Except share data)

September30,

December31,

2020

2019

U.S.$ inthousands

Unaudited

Audited

ASSETS

Current Assets:

Cash and cash equivalents

$

24,770

$

536

Short-term deposit (Note 4)

4,038

33

Other accounts receivable

1,473

2,359

Prepaid expenses and other current assets (Note 5)

56

432

Total current assets

30,337

3,360

Long-Term Assets:

Prepaid expenses and other long-term assets

27

32

Operating lease right of use asset (Note 6)

1,377

2,182

Property and Equipment, Net

950

960

Total Long-Term Assets

2,354

3,174

Total assets

$

32,691

$

6,534

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current Liabilities:

Accounts payable

$

3,283

$

14,677

Accrued expenses

917

1,000

Operating lease liability (Note 6)

1,216

1,263

Other accounts payable

1,013

714

Total current liabilities

6,429

17,654

Long-Term Liabilities:

Operating lease liability (Note 6)

284

1,103

Total long-term liabilities

284

1,103

Total liabilities

$

6,713

$

18,757

Stockholders' Equity (deficit):

Stock capital: (Note 7)

12

11

Common Stock of $0.00005 par value - Authorized: 100,000,000 shares at September 30, 2020 and December 31, 2019 respectively; Issued and outstanding: 31,567,592 and 23,174,228 shares at September 30,2020 and December31,2019 respectively.

The rest is here:
BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update - PRNewswire

Bone Marrow Stem Cells Comments Off on BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update – PRNewswire | October 19th, 2020

Go here to see the original:
Reflect Scientific Awarded Patent for COVID Vaccine Capable- Self Powered, Low Temperature Controlled Bulk Shipping System

Global News Feed Comments Off on Reflect Scientific Awarded Patent for COVID Vaccine Capable- Self Powered, Low Temperature Controlled Bulk Shipping System | October 19th, 2020

– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain –

View post:
Cocrystal Pharma Provides Update on Influenza A Program

Global News Feed Comments Off on Cocrystal Pharma Provides Update on Influenza A Program | October 19th, 2020

NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Scott Henry, Managing Director, Senior Research Analyst and Head of Pharmaceuticals Research at ROTH Capital Partners, will host a webinar with the management team of Journey Medical Corporation (“Journey Medical”), a partner company of Fortress, on Wednesday, October 21, 2020, at 1:00 p.m. EDT. Speakers from Journey Medical will include Claude Maraoui, President and Chief Executive Officer, Robert Nevin, Chief Commercial Officer, and Nirav Jhaveri, Chief Financial Officer.

See the rest here:
Fortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners

Global News Feed Comments Off on Fortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners | October 19th, 2020

DAVIS, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, today released a letter to shareholders from Chief Executive Officer, Kevin Helash.

Continued here:
Marrone Bio Innovations Issues Shareholder Letter and Provides Operational Update

Global News Feed Comments Off on Marrone Bio Innovations Issues Shareholder Letter and Provides Operational Update | October 19th, 2020

JERSEY, Channel Islands, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2020 will be released before market open on Monday, Nov 2, 2020.

More:
Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call

Global News Feed Comments Off on Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call | October 19th, 2020

DALLAS, Texas, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present five abstracts at the American Society of Nephrology (ASN) Kidney Week 2020, which is being held virtually from October 22-25, 2020. The abstracts will highlight clinical and nonclinical data from novel drug formulations being developed for the treatment of chronic kidney disease (CKD), acute kidney injury (AKI), and COVID-19.

Read the original post:
Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020

Global News Feed Comments Off on Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020 | October 19th, 2020

Nicosia, Cyprus, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that it has closed the merger with BIOCOGENCY LABORATORIES. The new consolidated financials will include Slavich (http://www.slavich.ru), Slavich Trading House and related companies based in Spain, Ireland and Cyprus, with Kras Pharma (http://kraspharma.ru) and Bebig (http://en.bebig.ru/) being added in due course.

Read more from the original source:
Rafarma Closes Biocogency Merger

Global News Feed Comments Off on Rafarma Closes Biocogency Merger | October 19th, 2020

The U.S. Food and Drug Administration to provide an update on the Agency’s Comprehensive Plan for Tobacco and Nicotine Regulation The U.S. Food and Drug Administration to provide an update on the Agency’s Comprehensive Plan for Tobacco and Nicotine Regulation

See more here:
22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute’s Tobacco and Nicotine Products Regulation and...

Global News Feed Comments Off on 22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute’s Tobacco and Nicotine Products Regulation and… | October 19th, 2020

New in vivo data for colon cancer show anti-tumor immunity in 100% of mice

See the article here:
Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR...

Global News Feed Comments Off on Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR… | October 19th, 2020

MENLO PARK, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Third Quarter 2020 Financial Results on Monday, November 2, 2020, at 4:30pm Eastern Time.

More here:
Pacific Biosciences of California, Inc. Third Quarter 2020 Financial Results Call

Global News Feed Comments Off on Pacific Biosciences of California, Inc. Third Quarter 2020 Financial Results Call | October 19th, 2020

ORION CORPORATION STOCK EXCHANGE RELEASE INSIDE INFORMATION 19 OCTOBER 2020 at 20.35 EEST

The rest is here:
Orion upgrades full-year outlook for 2020

Global News Feed Comments Off on Orion upgrades full-year outlook for 2020 | October 19th, 2020

CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on October 29, 2020, to discuss its third quarter 2020 results and progress in its clinical programs. The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 7374769.

Link:
Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results

Global News Feed Comments Off on Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results | October 19th, 2020

Daix (France), October 19, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to odiparcil, the Company’s clinical-stage drug candidate for the treatment of MPS type VI (MPS VI), a rare and progressive genetic disorder.

See more here:
Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci

Global News Feed Comments Off on Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci | October 19th, 2020

WOBURN, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the appointment of Tanya Lewis to its Board of Directors, effective as of November 2, 2020.

Read the original post:
Replimune Appoints Tanya Lewis to the Board of Directors

Global News Feed Comments Off on Replimune Appoints Tanya Lewis to the Board of Directors | October 19th, 2020

ORIC-114 is a potential best-in-class inhibitor designed for brain penetrance and selectivity for exon 20 insertion mutations of EGFR and HER2

Originally posted here:
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program

Global News Feed Comments Off on ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program | October 19th, 2020